Lyell Immunopharma Q3 net loss $70.3M; GSK ends collaboration; LYL797 data delayed to H1 2024

Lyell Immunopharma, Inc.

2022-Q3 EPS reported -$0.71 revenue$36,297,000

Net loss $70.3M vs $48.9M YoY; non-GAAP net loss $43.7M vs $35.7M.
Cash $750.7M as of Sep 30, 2022; funding extends into 2026.
GSK terminates NY-ESO-1 programs LYL132/LYL331 effective Dec 24, 2022; not due to safety/efficacy.
IND cleared for LYL845 TIL therapy; initial data expected 2024.
LYL797 enrollment slower; initial data now expected first half of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported financial results for third quarter of 2022.

Period: third quarter of 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.